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Abstract: Hypertension is the number one diagnosis made by primary care physicians, placing
them in a unique position to prescribe the antihypertensive agent best suited to the individual
patient. In individuals with diabetes mellitus, blood pressure (BP) levels  130/80 mmHg
confer an even higher risk for cardiovascular and renal disease, and these patients will benefit
from aggressive antihypertensive treatment using a combination of agents. β‑blockers are play‑
ing an increasingly important role in the management of hypertension in high-risk patients.
β‑blockers are a heterogeneous class of agents, and this review presents the differences between
β‑blockers and provides evidence-based protocols to assist in understanding dose equivalence
in the selection of an optimal regimen in patients with complex needs. The clinical benefits
provided by β‑blockers are only effective if patients adhere to medication treatment long term.
β‑blockers with proven efficacy, once-daily dosing, and lower side effect profiles may become
instrumental in the treatment of hypertensive diabetic and nondiabetic patients.
Keywords: antihypertensive, blood pressure, atenolol, carvedilol, labetalol, metoprolol,
nebivolol
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Hypertension is one of the most common reasons for primary care physician visits and
the number one diagnosis during appointments.1 Approximately 65 million Americans
have hypertension, with a marked increase in prevalence among younger adults aged
18–39 years, which may be related to the high obesity incidence in this country.2,3 The
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC) guidelines are evidence-based recommendations that integrate
epidemiologic and clinical trial evidence about the health benefits associated with antihy‑
pertensive therapies into patient management decisions.4 The most recent JNC guidelines
(JNC7) recommend maintaining a target blood pressure (BP) of  140/90 mmHg in
patients with hypertension to reduce heart disease risk.5 To achieve BP control, the
majority of patients with hypertension will need at least two medications from differ‑
ent pharmacologic classes. Patients with compelling indications such as heart failure
(HF), myocardial infarction (MI), high coronary disease risk, and diabetes may need
more aggressive treatment with three agents (Table 1).5
Of particular concern is the patient with concomitant diabetes or who is at high risk
for diabetes. Patients with both hypertension and diabetes have a dramatically increased
risk for cardiovascular complications, such as stroke and chronic kidney disease.6 Data
from clinical studies emphasize the need for tight BP control in these patients. In the
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Table 1 Clinical trial and guideline basis for compelling indications for individual drug classes
High-risk condition
with compelling
indicationa

Thiazide-type
diuretic

β-Blocker

ACEI

ARB

Heart failure

X

X

X

X

X

X

Post-myocardial
infarction

High coronary
disease risk

X

X

X

Diabetes

X

X

X

X

X

X

Chronic kidney disease

Recurrent stroke
prevention

X

X

CCB

Ald Ant

Guideline and/or
clinical trial basisb

X

ACC/AHA heart failure
guidelines, MERIT-HF,
COPERNICUS, CIBIS,
SOLVD, AIRE,
  
TRACE,
Val-HeFT, RALES,
CHARM

X

ACA/AHA postmyocardial infarction
guidelines, BHAT, SAVE,
CAPRICORN, EPHESUS

X

ALLHAT, HOPE, ANBP2,
LIFE, CONVINCE,
EUROPA, INVEST

X

NKF-ADA Guidelines,
UKPDS, ALLHAT
NKF Guidelines,
Captopril Trial, RENAAL,
IDNT, REIN, AASK
PROGRESS

Notes: aCompelling indications for antihypertensive drugs are based on benefits from outcome studies or existing clinical guidelines; the compelling indication is managed
in parallel with the BP. bConditions for which clinical trials demonstrate benefit of specific classes of antihypertensive drugs used as part of an antihypertensive regimen to
achieve BP goal to test outcomes.
Copyright © 2003. Adapted with permission from Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.
Abbreviations: AASK, African-American Study of Kidney Disease and Hypertension; ACC/AHA, American College of Cardiology/American Heart Association;
ACEI, angiotensin-converting enzyme inhibitor; AIRE, Acute Infarction Ramipril Efficacy; Ald Ant, aldosterone antagonist; ALLHAT, Antihypertensive and Lipid Lowering
Treatment to Prevent Heart Attack Trial; ANBP2, Second Australian National Blood Pressure Study; ARB, angiotensin receptor blocker; BHAT, Beta-Blocker Heart Attack
Trial; CAPRICORN, Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction; CCB, calcium channel blocker; CIBIS, Cardiac Insufficiency Bisoprolol Study;
CONVINCE, Controlled Onset Verapamil Investigation of Cardiovascular Endpoints; COPERNICUS, Carvedilol Prospective Randomized Cumulative Survival; EPHESUS,
Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; EUROPA, European Trial on Reduction of Cardiac Events with Perindopril in Stable
Coronary Artery Disease; HOPE, Heart Outcomes Prevention Evaluation; IDNT, Irbesartan in Diabetic Nephropathy Trial; INVEST, International Verapamil SR/Trandolapril
Study; LIFE, Losartan Intervention for Endpoint Reduction; MERIT-HF, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure; NKF‑ADA, National
Kidney Foundation-American Diabetes Association; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; RALES, Randomized Aldactone Evaluation Study;
REIN, Ramipril Efficacy in Nephropathy; RENAAL, Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan; SAVE,
Survival and Ventricular Enlargement; SOLVD, Studies of Left Ventricular Dysfunction; TRACE, Trandolapril Cardiac Evaluation; UKPDS, UK Prospective Diabetes Study;
Val‑HeFT, Valsartan in Heart Failure Trial.

UK Prospective Diabetes Study (UKPDS), 1,148 patients
with type 2 diabetes and hypertension were randomized to
more intense or less intense BP control and achieved BPs
of 144/82 and 154/87 mmHg, respectively, using either
an angiotensin-converting enzyme inhibitor (ACEI) or a
β-blocker.7 Patients assigned to more intense BP control
experienced risk reductions of 24% in diabetes-related end‑
points, 32% in diabetes-related deaths, 44% in stroke, 56%
in HF, and 37% in microvascular endpoints. Treatment with
either ACEIs or β-blockers substantially reduced the risk of
death and diabetes-related complications.7,8
For patients with hypertension and diabetes, national
organizations such as the National Kidney Foundation
(NKF), American Diabetes Association (ADA), American
Association of Clinical Endocrinologists (AACE), and
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the JNC recognize the serious risk and recommend
BP control to 130/80 mmHg.5,9–11 Although national guide‑
lines emphasize the importance of maintaining BP control in
people with hypertension, it has been reported that only 33%
of physicians consider clinical practice guidelines as important
for providing optimal disease management.12 Moreover, only
25%–36% of all patients with hypertension reach target BP
goals, although with intensive medication monitoring and
titration up to 69% of patients may maintain BP control.13–16
An analysis of data from The National Health and Nutrition
Examination  Survey (NHANES) 1988 to 2000 found that
,30% of patients with diabetes achieved their target BP
(,130/85 mmHg).16 The American College of  Physicians
recommends  initiating  antihypertensive therapy with a
thiazide diuretic or an ACEI in patients with  hypertension
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and diabetes.17 In most cases, however, additional agents are
required to achieve BP goals.5,18 Indeed, patients who are
20/10 mmHg above their BP goal should initiate treatment
with two antihypertensive agents that have complementary
mechanisms in order to reach target BP and reduce cardio‑
vascular risk.5
The NKF, ADA, AACE, and JNC7 all include a
recommendation for the use of β‑blockers.5,9–11 Several
randomized controlled trials and meta-analyses have shown
that when monotherapy is used for essential hypertension,
β-blockers and diuretics are equally effective at lowering
BP compared with ACEIs, adrenergic receptor binders
(ARBs), and calcium channel blockers (CCBs).19–25 Patients
with hypertension and compelling indications such as HF
or diabetes may benefit from treatment with β-blockers
because they have antiatherogenic, antiarrhythmic, and
anti-ischemic properties.26–28 Clinical trials have demon‑
strated the beneficial effects of β‑blockers in patients with
coronary heart disease, post-MI patients, and patients with
diabetes.8,29–32

β-blockers for treatment
of hypertension
There is a need to improve hypertension management
in high-risk patients, and optimal therapy choice may
enhance both adherence and outcomes in the long term.
Despite their proven cardiovascular benefits, β-blockers
are underused for the treatment of hypertension in patients
with diabetes because of their perceived side effect
profile. 8,33,34 However, various agents within the class
of β-blockers have different pharmacologic properties,
including receptor antagonism effects, resulting in variable
clinical outcomes in terms of hemodynamic and metabolic
effects and tolerability across the spectrum of cardiovas‑
cular diseases.35–40
Concerns about the use of β-blockers as first-line agents
for hypertension have been raised because of a 2005 metaanalysis that found β-blockers do not significantly reduce
cardiovascular events, especially stroke, compared with other
antihypertensive drug classes.41 However, atenolol was the
β-blocker evaluated in three quarters of the studies included
in this meta-analysis (the others were propranolol, oxprenolol,
metoprolol, and pindolol). Atenolol does not reduce all-cause
mortality in hypertension long term compared with other
agents.41 Another meta-analysis of five randomized controlled
trials with more than 17,000 patients found  significantly
higher mortality (relative risk [RR] = 1.13, 95% confidence
interval [CI] = 1.02, 1.25) with atenolol compared with
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other agents.22 These analyses raise questions about whether
atenolol is suitable for high-risk patients with hypertension.
Atenolol, metoprolol (β1-selective blockers), and
propranolol (a β1-, β2-blocker) are associated with decreased
insulin sensitivity and lipid metabolism.35,41,42 However, the
third-generation nonselective β-blocker carvedilol does
not have a negative effect on glycemic control and has
an overall neutral effect on lipids.35,42,43 Similar effects on
metabolic parameters have been observed with nebivolol
in patients with hypertension and diabetes.44 Moreover,
in the Glycemic Effect in Diabetes Mellitus: CarvedilolMetoprolol Comparison in Hypertensives (GEMINI) study,
the occurrence and perceived burden of diabetes-related
symptoms was lower with carvedilol than with metoprolol
tartrate in patients already taking an ACEI or ARB in addi‑
tion to diabetes and lipid-lowering therapies.45 Half of the
patients required additional BP-lowering agents, starting
with a diuretic. Improvements in symptom burden observed
in GEMINI added to the established efficacy and tolerability
profile of carvedilol, and support its continued use in patients
with hypertension and diabetes. AACE recognizes the benefit
of the vasodilating properties of carvedilol and nebivolol and
has suggested that these agents may be beneficial in patients
with hypertension and diabetes.9
The third-generation β-blockers such as labetalol,
c arvedilol, and nebivolol reduce BP in part through
l owering peripheral vascular resistance (vasodilation)
instead of  reducing cardiac output as done by the older,
traditional β-blockers.46 The vasodilatory action of labetalol,
carvedilol, and nebivolol may lessen the incidence of some
adverse events associated with traditional β-blockers. For
example, peripheral vasodilation may reduce the incidence
of cold extremities and lessen the effect on glucose
metabolism.47,48
Noncompliance with antihypertensive medications is
common and is a major cause of inadequate BP  control.49

Polypharmacy is one common reason for medication
nonadherence, but a recent study of patients with  diabetes
taking an average of 4.1 medications found that unreported side
effects were also responsible for selective noncompliance.50
β-blockers have been associated with many adverse effects,
including worsening glycemic control, fatigue, cold
extremities, and sexual dysfunction. Studies have reported that
physicians perceive β‑blockers to be less well tolerated than the
other three antihypertensive classes of drugs, a point of view
that is bolstered by studies such as the Losartan Intervention for
Endpoint Reduction (LIFE) trial and can influence prescription
preferences.51,52 However, a number of randomized controlled
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trials show that β-blockers and diuretics are equally or better
tolerated than ACEIs or CCBs.19,20,24,53–55

Adherence in hypertension

The clinical benefits provided by β-blockers are only effective
if patients adhere to medication treatment correctly and on
a long-term basis. Many factors may contribute to poor
medication adherence, but side effect profiles of drugs and
the complexity of dosing regimens are likely to be major
factors. Reducing pill burden by prescribing a once-daily
agent (although not studied specifically in β-blocker trials)
has been shown to increase adherence, including in patients
with hypertension.56
In a large-scale study of medication adherence among
2,325 patients with hypertension, only 39% of patients
maintained therapy with one or more antihypertensive drugs
throughout the 10-year followup period.57 Approximately
22% of patients temporarily stopped and restarted treatment,
and 39% stopped treatment permanently. More patients
starting on diuretics and β-blockers stopped treatment
(odds ratio [OR] = 1.15; 95% CI = 0.87, 1.52) compared
with those starting on dihydropyridine calcium antagonists
(OR = 0.54; 95% CI = 0.34, 0.84) and ACEIs (OR = 0.38; 95%
CI = 0.27, 0.55). Patients also showed higher persistence when
started on combination therapy (OR = 0.29; 95% CI = 0.14,
0.54 compared with diuretics) or when initially treated by a
cardiologist (OR = 0.82; 95% CI = 0.61, 0.97) or internist
(OR = 0.80; 95% CI = 0.62, 0.98) compared with a general
practitioner.57 Two factors in patient adherence to medication
are the perceived symptoms and the perception of the therapy
importance. It is important that the side effects of prescribed
therapies are not worse than the disease symptoms, and that
dosing instructions are as simple as possible for patients taking
numerous medications. This is particularly problematic in the
treatment of hypertension, because some medications may
produce more adverse symptoms than the disease itself.58 Low
compliance rates are prevalent in these patients.59 Patients with
hypertension who have uncontrolled BP as a result of their
poor medication-taking behavior remain at risk for serious
morbidity and mortality (eg, stroke, myocardial infarction,
and kidney failure). Patients with diabetes and comorbid
hypertension and/or dyslipidemia are at particularly high risk
for nonadherence because of the polypharmacy required to
treat hyperglycemia, hypertension, and/or hyperlipidemia.
In a study of compliance with prescribed medications in
357 patients seen by family practice physicians and internists,
the rates of adherence in both patients with HF (n = 123)
and patients with diabetes (n = 234) was less than optimal.60
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Patients were taking up to 14 different drugs, and an asso‑
ciation was observed between the number of drugs and
medication-taking errors, including omission (proportion
of drugs prescribed by the physician that the patient was not
taking), commission (proportion of prescription drugs the
patient was taking that the physician had not prescribed),
scheduling misconception (proportion of prescribed drugs
taken by the patient for which the patient did not know the
correct schedule), and scheduling noncompliance (proportion
of prescribed drugs taken by the patient for which the patient
knew the correct schedule but did not take as prescribed).
When all types of medication-taking errors were combined,
the average total error rate was 58%. Error rates for both
commission and scheduling misconception errors increased
as the complexity of the regimen (as measured by dosing
frequency) increased.60
Reducing pill burden by prescribing a once-daily agent
may increase adherence, as shown in a systemic review of
hypertension studies in which the highest adherence was
found with once-daily dosing and declined as the daily dose
frequency increased.56 To improve outcomes among patients
with hypertension, programs to detect poor medication adher‑
ence and support long-term persistence must be developed
and successfully implemented, using antihypertensive agents
that promote and aid adherence through simplified dosing
and high tolerability.61

Choosing β-blockers for optimal
treatment of high-risk
hypertensive patients
Atenolol
In clinical studies, especially the studies evaluated in recent
meta-analyses, atenolol 50 mg to 100 mg is typically a
once-daily therapy.41,62–64 However, this atenolol regimen
may not provide a full 24 hours of blood pressure control.
This is illustrated by a small, open-label study involving
36 patients with hypertension who were receiving hydro‑
chlorothiazide 12.5 mg, whereby adding 50 mg atenolol or
metoprolol succinate once daily in the morning (force-titrated
to 100 mg at four weeks) provided lowered systolic blood
pressures (SBP) during the midnight to six o’clock hours with
metoprolol tartrate (-7 mmHg), but not atenolol (3 mmHg;
P = 0.03).65 Additionally, in another study of atenolol (50 to
100 mg once daily), the decrease in diastolic blood pressure
(DBP) values in the last six hours of the 24‑hour dosing
period was significantly less than in the previous 18 hours
(P  0.01).66 Night time and early morning BP control is
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important because it is during these times that increases in
cardiovascular morbidity are observed.65 The results of these
studies may explain, in part, the reduced benefit regarding
cardiovascular events attributed to β‑blockers (primarily
atenolol) compared with other antihypertensive agents in
the previously mentioned meta-analysis.41 Moreover, delay‑
ing an atenolol dose may have clinically relevant effects on
BP control.
Atenolol was also found to decrease insulin sensitivity
and increase triglyceride levels and risk of new-onset
diabetes compared with other antihypertensive classes in
two large studies.67–69 In patients at high risk for diabetes or
dyslipidemia or who develop these conditions, atenolol may
not be appropriate.

Metoprolol

Metoprolol is a relatively β1-adrenergic receptor selective
agent, but loses this selectivity at higher plasma concentra‑
tions.70 This agent has two formulations; an immediaterelease (tartrate) and an extended-release (succinate).71 The
immediate-release formulation is a twice-daily regimen,
because at 100 mg once daily, metoprolol tartrate does not
provide clinically relevant β1-adrenergic receptor blockade
(assessed by exercised-induced tachycardia) in the last six
hours of the 24-hour dosing period.71 Additionally, maximum
plasma concentrations have been shown to be as much as
four-fold higher with the immediate-release formulation
compared with the extended-release formulation at 100
mg.71 If patients with hypertension are unable to tolerate
metoprolol tartrate, a recommended alternative treatment
endorsed by pharmacists is metoprolol succinate at the total
daily  metoprolol tartrate dose.72 If  metoprolol succinate
is not  tolerated, another β‑blocker such as carvedilol or
bisoprolol can be started 24 hours after the last metoprolol
dose (see later for carvedilol dosing  equivalence and see
Table 3).72

Labetalol

Labetalol was the first β-blocker to provide comprehensive
adrenergic blockade.73 However, because of a short half-life
(six to eight hours), labetalol is administered as a twice-daily
medication and is not as convenient as once-daily dosing
for patients with hypertension who are  taking multiple
medications.73 A key property of labetalol is that it lowers BP
quickly (orally, within two hours; intravenously, in 10 minutes)
and in a steady manner without clinically relevant changes in
heart rate or cardiac output.73 Therefore, labetalol is ideally
suited for use in hypertensive emergencies.74 Labetalol has
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also been found to be useful in the treatment of hypertension
during pregnancy, especially severe hypertension, given that
ACEIs and ARBs are  contraindicated because of adverse
effects.75
Labetalol has been well tolerated in general practice
in patients with all stages of hypertension. A review of 11
general practice studies involving 8573 patients reported that
tiredness, dizziness, headache, and upper gastrointestinal
symptoms were the most common adverse events during
labetalol treatment.76 Moreover, except for headache, patients
treated with labetalol 400 mg reported fewer of the common
adverse events compared with propranolol and slow‑release
oxprenolol. However, the incidence of adverse events dur‑
ing labetalol treatment appeared to be dose-dependent. No
published reports were found with labetalol in patients with
diabetes or other conditions with a high risk of cardiovascular
events. Nevertheless, in 81 patients with severe hypertension
who received either labetalol-based or methyldopa-based
therapy for up to one year, labetalol-based therapy provided
hypertension control (diastolic BP  90 mmHg) in 40% of
patients, with nausea being the most commonly reported
adverse event.77

Nebivolol
Nebivolol 5 mg is administered once daily and has been
shown in clinical trials to be well tolerated in patients with
hypertension, although there is no indication for ts use after
an MI or in patients with HF. A recent open-label, six-week
study of nebivolol (5 to 10 mg daily) in patients with mild
hypertension (n = 6356) reported no serious adverse events
and only 0.5% of patients reported any adverse event.78
In a meta-analysis of 12 studies involving 2653 patients
with hypertension, the adverse events reported for nebivolol
5 mg were higher than placebo (OR = 1.16; 95% CI,
0.76–1.67; P = 0.482) but lower than other antihypertensive
agents combined (ACEIs, ARBs, CCBs, atenolol, metoprolol
tartrate, and bisoprolol; OR = 0.59; 95% CI, 0.48–0.72;
P , 0.001).79 In a three-month, open-label study in 2838
patients with hypertension and Type 2 diabetes, nebivolol
(2.5 to 10 mg daily) lowered BP to the recommended goal
(,130/80 mmHg) in 9.6% of patients and to a diastolic
BP of  90 mmHg in 88% of patients.44 There was a small
increase in physical capabilities that achieved statistical
significance (P , 0.001). Reported adverse events were
low, comprising 0.3% of patients, with headache, fatigue,
and nausea each reported in one patient. At study entry,
approximately 40% of patients were receiving ACEIs and
20% were receiving an ARB.
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Compared with atenolol 50 mg daily in patients with
hypertension (n = 366), nebivolol 5 mg daily reduced the
number of patients who reported fatigue (eight versus four,
respectively).80 However, a similar number of patients reported
dizziness (two versus three, respectively) and headache (four
versus three, respectively). It has been reported in a recent
review that similar results were obtained from a clinical trial
comparing nebivolol with metoprolol.81

Table 2 Recommended algorithm for replacing carvedilol with
carvedilol CR in patients with hypertension
Current dose of carvedilol
6.25 mg (3.125 mg BID)

Starting dose of
carvedilol CRb
Wait 12 hoursa

10 mg QD

12.5 mg (6.25 mg BID)

20 mg QD

25 mg (12.5 mg BID)

40 mg QD

50 mg (25 mg BID)

80 mg QD

Notes: Suggestion for patients: Take the nighttime dose of carvedilol BID and start
carvedilol CR the next morning. bWhen switching from carvedilol 12.5 mg or 25 mg
BID, a lower starting dose of COREG® CR may be considered for elderly patients
(65 years) or those at increased risk of hypotension, dizziness, or syncope. Subsequent titration to higher doses should, as appropriate, be made after an interval of
at least two weeks. Recommendations are based on the author’s opinion, Coreg CR
prescribing information,82 and data from Fonarow.88
Abbreviations: BID, twice daily; CR, controlled release; QD, once daily.
a

Carvedilol CR
The availability of carvedilol controlled-release (carvedilol
CR), a once-daily formulation of carvedilol, allows for the
choice of a β-blocker that does not have adverse effects
on glycemic control and is also convenient for patients.
Carvedilol CR was approved by the US Food and Drug
Administration (FDA) with the same indications as the
original twice-daily formulation (hypertension, post-MI with
left ventricular  dysfunction, and HF).82 When  prescribing
any new medication, the discussion of adverse events (side
effects) is important because it may be a barrier to patient
adherence. Carvedilol CR has been well tolerated in the
clinical trials conducted so far in patients with hypertension
and with left ventricular dysfunction.83,84 In patients with
uncomplicated hypertension, carvedilol CR was tolerated
without an increase in total adverse events at the highest dose
(80 mg once daily) compared with placebo.85
Recent studies have shown that carvedilol CR is effective
in lowering BP. In a randomized, placebo-controlled study
that compared three doses of carvedilol CR (20, 40, and
80 mg once daily) with placebo in patients with essential
hypertension, the 24-hour DBP fell in the placebo group
and the three carvedilol CR groups (P  0.001, trend for all
carvedilol CR doses compared with placebo).85 The mean
SBP reduction at peak dose with carvedilol CR 80 mg was
-15.3 mmHg.86

Dosing equivalence of carvedilol
and carvedilol CR
Carvedilol CR has been shown to be therapeutically
equivalent to carvedilol, but with the benefit of once-daily
dosing. A number of investigations demonstrated that
the  pharmacokinetic and pharmacodynamic properties
are  equivalent between twice-daily carvedilol and oncedaily carvedilol CR; the two formulations were shown
to be  equivalent in all doses used in hypertension.87 For
hypertension treatment, carvedilol CR is available at doses
of 10, 20, 40, and 80 mg; the equivalent carvedilol doses
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are shown in Table 2.82,88 It is the author’s opinion, based
on Fonarow et al,88 that most patients currently on a stable
carvedilol dose should start the equivalent carvedilol CR
dose the day following their last evening dose of carvedilol.
However, a recent update to the carvedilol CR prescribing
information suggests that when switching from carve‑
dilol 12.5 mg or 25 mg twice daily, a lower starting dose
of carvedilol CR may be considered for elderly patients
(65 years) or those at increased risk of hypotension, diz‑
ziness, or syncope. Subsequent titration to higher doses
should, as appropriate, be made after an interval of at least
two weeks.

Dose equivalence of other
β-blockers and carvedilol CR
It is important to understand dose equivalence among
β-blockers for the selection of an optimal regimen in patients
with changing and complex needs, especially in patients who
develop dyslipidemia or diabetes. The dose  equivalencies
shown in Table 3 are based on clinical experience and were
chosen to maintain similar BP lowering levels. Replacing
another β‑blocker with carvedilol CR is generally safe
and well tolerated, but patients should be monitored to
ensure medication compliance, degree of BP lowering,
and  tolerance. Possible adverse events associated with
α-blockade are dizziness and postural hypotension.
The recommended starting dose of carvedilol CR in
patients with hypertension is 20 mg once daily. Although
the prescribing information for carvedilol CR states that
uptitration should occur at one to two week intervals, it is
the author’s opinion that in situations where carvedilol CR
is replacing another β-blocker, uptitration should occur at
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Table 3 Suggested dose equivalences between other β-blockers and carvedilol CR in hypertension
Current β-blocker

Carvedilol CR

Atenolol
50 mg QDc
75 mg QD

Starting dosea

Uptitration (after several days
to one week) as toleratedb

Carvedilol CR

Carvedilol CR

Wait 24 hours from last dose
of once‑daily atenolol

20 mg QD

40 mg QD

40 mg QD

80 mg QD

Wait 12 hours from last dose
of metoprolol tartrate

20 mg QD

40 mg QD

40 mg QD

80 mg QD

40–80 mg QD

80 mg QD

20 mg QD

40 mg QD

40 mg QD

80 mg QD

40–80 mg QD

80 mg QD

Metoprolol tartrate
25–50 mg BID
75–100 mg BID
100 mg BID
Metoprolol succinate
50–100 mg QD
150–200 mg QD

Wait 24 hours from last dose
of metoprolol succinate

200 mg QD

Notes: In clinical trials, carvedilol CR was initiated in β-blocker-naive patients at 20 mg. The recommendations in this table are based on the author’s clinical and research
experience and, therefore, recommend switching patients already on a medium to high dose of another β-blocker to a medium to high dose of carvedilol CR. A caveat, however:
older patients (65 years), patients with diabetic neuropathy, or those predisposed to orthostatic hypotension should generally start at 20 mg if on a low dose of another
β-blocker and 40 mg if on a high dose of another β-blocker. Such patients may then be uptitrated as tolerated; switching directly to 80 mg is not recommended in these patients.
Physicians should closely monitor all patients to avoid possible worsening of BP and increases in heart rate after switching to 20 or 40 mg of carvedilol CR, which would call
for a quicker uptitration. bUptitrate to achieve BP goal. Maximal dose is 80 mg daily (equivalent to 25 mg of carvedilol BID). cIf patients are on a dose of atenolol lower than
50 mg (ie, 25 mg/day) it is unclear what the exact dose of carvedilol CR would be; however, patients at this low a dose should not be started on a dose higher than 20 mg of
carvedilol CR.
Notes: Physicians should be guided by their own judgment and experience in choosing doses when switching between drugs.
Abbreviations: BID, twice daily; QD, once daily.
a

two- to three-day intervals as tolerated. Before prescribing
carvedilol, all other medications should be stable. Other
agents with vasodilatory properties (such as CCBs,
nitrates, or other  antihypertensives) should not be added
to the patient’s  regimen immediately before or during the
adjustment period.

Conclusions
Hypertension is the most common diagnosis in the primary
care setting and can only be treated properly if the patient
adheres to the medication regimen. In general,  adherence
to  antihypertensive drugs is suboptimal and may be
further decreased by complicated drug regimens. Choice
of antihypertensive therapy is a contributing factor to both
medication  adherence and clinical outcomes. Even within
a single antihypertensive class, such as the β‑blockers, the
clinical profile of the members may vary greatly. Consequently,
information about the dosing, efficacy,  tolerability, and
pharmacokinetic properties of the various agents is necessary
in order to select the β-blocker that is most appropriate for
the individual patient. Although all β-blockers are effective
in reducing BP, they have very different hemodynamic, toler‑
ability, and metabolic profiles. The earlier β-blockers, atenolol
and metoprolol, may require a twice-daily regimen and may
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result in glucose and lipid metabolism abnormalities. Nebivo‑
lol is a once-daily β-blocker for the treatment of hypertension
with neutral metabolic properties; however, it is not indicated
after an MI or if a patient progresses to HF. The availability
of carvedilol CR, a once-daily formulation of carvedilol, will
result in an easier dosing regimen while retaining the neutral
metabolic properties that make carvedilol a desirable agent
in high-risk patients with hypertension.
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